IPI-145 supplier|cas 1201438-56-3 |DC Chemicals|Supplier|Price|Buy  

IPI-145 supplier|cas 1201438-56-3 |DC Chemicals|Supplier|Price|Buy

DC Chemicals Supply: IPI-145 supplier,cas 1201438-56-3, Cat No. DC5072, In stock

Contact: website: www.dcchemicals.com,

sales@dcchemicals.com,order@dcchemicals.com,info@dcchemicals.com,

Tel: +86-21-61454686;Fax:+86-21-61642830；

Product name: IPI-145, Synonym:　IPI145; IPI 145; IPI-145. INK-1197; INK 1197; INK1197, Cat No. DC5072, Cas: 1201438-56-3, Chemical Name:N/A, Molecular Formula: C22H17ClN6O, MW: 416.86

IPI-145,cas 1201438-56-3, Purity: >98%. Best Price and quality in the market,DC Chemicals,Primary Manufacturer, confirmed by HNMR and HPLC. IPI-145 is an orally bioavailable, highly selective and potent small molecule inhibitor of the delta and gamma isoforms of phosphoinositide-3 kinase (PI3K) with potential immunomodulating and antineoplastic activities. Upon administration, PI3K delta/gamma inhibitor IPI 145 prevents the activation of the PI3K delta/gamma-mediated signaling pathways which may lead to a reduction in cellular proliferation in PI3K delta/gamma-expressing tumor cells. Unlike other isoforms of PI3K, the delta and gamma isoforms are overexpressed primarily in hematologic malignancies and inflammatory and autoimmune diseases. By selectively targeting these PI3K isoforms, PI3K signaling in normal, non-neoplastic cells is minimally or not affected which would result in a more favorable side effect profile.

IPI-145, also known as INK-1197, is an orally bioavailable, highly selective and potent small molecule inhibitor of the delta and gamma isoforms of phosphoinositide-3 kinase (PI3K) with potential immunomodulating and antineoplastic activities. Upon administration, PI3K delta/gamma inhibitor IPI 145 prevents the activation of the PI3K delta/gamma-mediated signaling pathways which may lead to a reduction in cellular proliferation in PI3K delta/gamma-expressing tumor cells. Unlike other isoforms of PI3K, the delta and gamma isoforms are overexpressed primarily in hematologic malignancies and inflammatory and autoimmune diseases. By selectively targeting these PI3K isoforms, PI3K signaling in normal, non-neoplastic cells is minimally or not affected which would result in a more favorable side effect profile.